This page is free and needs no sign-up. It reproduces material from How to Read a Biopharma License and Collaboration Agreement by Julian R. Sterling so you can print it or keep it open while you work.
To print it, use your browser's print button. Figures are as stated in the book; check the official source before relying on any of them.
Appendix B: The Reading Checklist: Forty Questions for Any License and Collaboration Agreement
Use this checklist on the first read of any license and collaboration agreement, and again before a call with counsel or a board. Each question is followed by one sentence on why it matters. The chapter that explains the point is named in brackets. Ellisford and Wexbury, the fictional licensor and licensee of this book, serve as the reference pair: if you cannot answer a question for them from the clauses, you cannot answer it for the real contract either.
Architecture and Grant (Questions 1 to 6)
- Who are the parties, and are the licensing entity and the paying entity the same? Why: a promise to pay is only as good as the company that makes it, and a subsidiary may be the weaker credit [chapter 1].
- Which documents make up the deal: the main agreement, side letters, a supply agreement, an equity purchase agreement? Why: payments and protections often sit in a document other than the one you were given [chapter 1].
- If the agreement was filed publicly, which terms are marked as hidden, and can the missing figure be rebuilt from the rest? Why: a hidden rate or period changes the value, and the layout of the article often shows what is missing [chapter 1].
- Is the grant exclusive, and exclusive against whom: the licensee only, or the licensor too? Why: a license that lets the licensor keep making or selling the product is worth less to the licensee [chapter 2].
- How are the field and the territory defined, and what does the licensor keep? Why: retained rights, such as the rights Ellisford keeps in mainland China, Hong Kong and Macau, shape both the competition and the need for shared data [chapter 2].
- Who may sublicense, to whom, and with what consent? Why: sublicensing decides who ends up selling the product, and whether the licensee stays liable for them [chapter 2].
Upfront, Equity and Milestones (Questions 7 to 12)
- Is the upfront payment non-refundable and non-creditable, and when exactly is it due? Why: these two words decide whether the money is final or can be netted against later amounts [chapter 3].
- Does the licensee also buy shares, and at what price compared with the last private round? Why: a premium or a discount changes how much of the headline is a payment for the license and how much is a payment for the shares [chapter 3].
- What event triggers each milestone, who decides that it has happened, and what is the payment clock? Why: vague triggers and long clocks move cash and open disputes [chapter 3].
- Is each milestone paid once, or again for a second indication, a new formulation or a new territory? Why: a repeat payment can make a deal worth much more than the headline suggests [chapter 3].
- Which milestones depend on sales, and how is the threshold measured? Why: a sales milestone tied to a calendar year can be missed by a day, and net sales may differ from what the licensor expects [chapter 3].
- What is the headline value, and what is its risk-adjusted value once probabilities and timing are applied? Why: the headline is a ceiling, not an expectation, and the gap between them is the real price of the risk [chapter 3].
Royalties and Reductions (Questions 13 to 20)
- What are the royalty tiers, and does each rate apply to the whole of sales or only to the slice inside its band? Why: the two readings produce very different payments [chapter 4].
- How is net sales defined, and which deductions are allowed? Why: every deduction lowers the royalty before any rate is applied [chapter 4].
- How are royalties paid, in what currency, and with what reports and audit rights? Why: a right without a report to check it is hard to use [chapter 4].
- What is the royalty term in each country, and which limb of the test controls: a patent, a number of years or regulatory exclusivity? Why: the term fixes how long the stream lasts and in which countries [chapter 4].
- What happens to the rate when the last patent claim ends or exclusivity ends? Why: a step-down at that point can cut the stream sharply even though sales continue [chapter 4].
- What reduction applies when a biosimilar or another competing product is sold, and does it need only a sale or also an approval? Why: the trigger decides when the cut starts and how easily either side can argue about it [chapter 5].
- May the licensee deduct payments to third-party patent holders, and what share of them? Why: a deduction passes part of the cost of a third-party license to the licensor [chapter 5].
- Is there a floor on the combined reductions, and is it measured by country or across the territory? Why: the floor is the limit of the licensor's exposure, and the unit of measure changes how much it protects [chapter 5].
Governance and Diligence (Questions 21 to 26)
- Who sits on the joint steering committee, how often does it meet, and does it have a vote or only a voice? Why: a committee with no real decisions is a reporting forum, not governance [chapter 6].
- What happens at a deadlock, and who has the final say on which matters? Why: the last word usually belongs to the party carrying the cost, and it is the most revealing sentence in the article [chapter 6].
- What can the final say never be used for? Why: the limits protect the licensor from having a payment or an obligation reshaped through a decision that looks operational [chapter 6].
- How is commercially reasonable efforts defined, and against what comparison group? Why: the group sets the bar, and a loose group makes the duty almost empty [chapter 7].
- Are there hard obligations, such as a minimum spend, a dosing date, a filing date or a launch window? Why: dated duties are easy to check, which is why they are the ones that can be enforced [chapter 7].
- What remedy follows a missed obligation, after what grace and cure period, and is it limited to a country or to the whole territory? Why: a remedy that is too harsh may never be used, and one that is too soft does not protect the licensor [chapter 7].
Options and Intellectual Property (Questions 27 to 32)
- Does the licensee or the licensor hold any option, and over what: a second indication, a new program or a share of profits? Why: an option is a separate bet with its own price and its own clock [chapter 8].
- What starts the exercise window, how long is it, and what must the licensor deliver first? Why: a late or thin data package can change the value of the choice [chapter 8].
- Is the closing of the option conditioned on an antitrust waiting period, and who bears the risk of delay? Why: the condition decides when the money moves and what each side may do in between [chapter 8].
- If the licensor may opt in to co-development, co-promotion or profit sharing, what does it pay, what does it give up, and what does it share if the launch loses money? Why: sharing profits means sharing losses, which can change the choice [chapter 8].
- Who owns the patents, who prosecutes them, and who pays? Why: the party that controls prosecution controls how strong and how long the patents are [chapter 9].
- Who may enforce the patents first, what happens if that party does not act, and how are recoveries split? Why: a right to sue that nobody has to use leaves the product exposed [chapter 9].
Regulatory and Supply (Questions 33 to 35)
- Who holds the regulatory filings, and does the licensor keep a right of reference for the territory it retained? Why: filings and data are the practical assets, and losing access to them can block a program [chapter 10].
- Who keeps the safety database, and is there a safety data exchange agreement with defined duties? Why: both sides must report to regulators, and a gap in the exchange is a compliance risk for each [chapter 10].
- Who supplies the drug, at what price, and when does manufacturing know-how move to the licensee? Why: a supply price and a transfer date decide the licensee's cost and its dependence on the licensor [chapter 10].
Termination, Change of Control and Bankruptcy (Questions 36 to 40)
- For what reasons may each side terminate, and with what notice and cure period? Why: the shortest route out tells you how permanent the deal really is [chapter 11].
- What happens on termination: what reverts, what is transferred, who pays the wind-down, and what survives? Why: the exit terms decide what the licensor holds after a failure and how fast it can move on [chapter 11].
- May the agreement be assigned, and what happens if either party is acquired? Why: a deal made with one company may end up with a different owner, who may sell a competing product [chapter 11].
- Does the agreement protect the licensee if the licensor files for bankruptcy, and does it name section 365(n)? Why: the licensee's right to keep using the licensed rights may depend on how the clause is drafted [chapter 11].
- Having read all of the above, can you trace every payment in the agreement to a date and a trigger, as chapter 12 does for Ellisford and Wexbury? Why: if one payment cannot be traced, the agreement is not yet understood [chapter 12].